Topics

MHRA suspends license for Picato over concerns of skin malignancy risk

07:07 EST 14 Feb 2020 | European Pharmaceutical Review
Medicine gel coming out of tube

The marketing license for ingenol mebutate gel (Picato) has been suspended by the MHRA due to studies showing an increased risk of skin malignancies from the drug.

The post MHRA suspends license for Picato over concerns of skin malignancy risk appeared first on European Pharmaceutical Review.

Original Article: MHRA suspends license for Picato over concerns of skin malignancy risk

NEXT ARTICLE

More From BioPortfolio on "MHRA suspends license for Picato over concerns of skin malignancy risk"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...